Community Research and Development Information Service - CORDIS

Horizon 2020 project information and now also report summaries are available on CORDIS. All H2020 projects can be downloaded from the EU Open Data Portal .

My refinements


Download results of this page


Refine by:

Country

Argentina (1)
Australia (1)
Austria (100)
Belgium (175)
Bulgaria (5)
Chile (1)
Croatia (8)
Cyprus (10)
Czech Republic (42)
Denmark (144)
Estonia (9)
Finland (57)
France (299)
Germany (426)
Greece (61)
Hungary (22)
Iceland (7)
Ireland (69)
Israel (38)
Italy (247)
Japan (1)
Latvia (7)
Lithuania (7)
Luxembourg (10)
Malaysia (1)
Malta (1)
Netherlands (319)
Norway (59)
Poland (45)
Portugal (69)
Romania (6)
Serbia (2)
Slovakia (7)
Slovenia (23)
Spain (257)
Sweden (157)
Switzerland (113)
Turkey (7)
Ukraine (1)
United Kingdom (468)
United States (1)
Uruguay (1)

Content Type

Project (530)
News (10)
Event (24)
Report Summary (106)
Programme (14)
Project Deliverable (244)
Project Publication (219)

Language

Deutsch (3)
English (1248)
Español (3)
Français (3)
Italiano (3)
Polski (3)

Advanced search

Results 1 - 10 of 1269
Results/page:
12 3 4 5 6 7 8 9 10 > >| 
Exploiting MELanoma disease comPLEXity to address European research training needs in translational cancer systems biology and cancer systems medicine
ID: 642295
Start date: 2014-12-01, End date: 2018-11-30
Novel treatment options and associated personalised, patient-tailored therapies need to be explored and developed for highly heterogeneous and chemotherapy resistant cancers, such as malignant melanoma. This can only be achieved by industry-academia collaborations in newly...
Programme: H2020-EU.1.3.1.
Record Number: 193900
Last updated on: 2017-07-19
Periodic Reporting for period 1 - MEL-PLEX (Exploiting MELanoma disease comPLEXity to address European research training needs in translational cancer systems biology and cancer systems medicine)
In the absence of personalised and optimised treatment, great numbers of cancer patients suffer from inefficient therapies. Malignant melanoma exemplifies a largely chemotherapy-resistant, highly heterogeneous and aggressive cancer. Novel treatment options for personalised...
Programme: H2020-EU.1.3.1.
Record Number: 205099
Last updated on: 2017-11-17
MELanoma GENetics - understanding and biomarking the genetic and immunological determinants of melanoma survival
ID: 641458
Start date: 2015-06-01, End date: 2019-05-31
MELGEN (MELanoma GENetics) – understanding and biomarking the genetic and immunological determinants of melanoma survivalThe MELGEN European Training Network (ETN) will create an environment for long-term, collaborative, inter-sectorial cancer genetics research with the...
Programme: H2020-EU.1.3.1.
Record Number: 197243
Last updated on: 2016-12-08
Periodic Reporting for period 1 - MELGEN (MELanoma GENetics - understanding and biomarking the genetic and immunological determinants of melanoma survival)
The MELGEN European Training Network (ETN) and Consortium was designed as an environment for long-term, collaborative, cancer genetics research with the ultimate aim of improving precision (personalised) medicine. Comprised of 17 PhD early stage researchers (ESRs) and their...
Programme: H2020-EU.1.3.1.
Record Number: 205068
Last updated on: 2017-11-17
Zero and ultra-low field nuclear magnetic resonance
ID: 766402
Start date: 2018-02-01, End date: 2022-01-31
Nuclear magnetic resonance (NMR) is a powerful technique employed in many areas of modern science and industry. While a seemingly indispensable element of NMR is a strong (>5 T) magnetic field, recent progress in physics and chemistry have enabled detection of NMR signals at...
Programme: H2020-EU.1.3.1.
Record Number: 211913
Last updated on: 2017-08-31
European Doctorate in ARchaeological and Cultural Heritage MATerials science
ID: 766311
Start date: 2018-04-01, End date: 2022-03-31
The ED-ARCHMAT (European Doctorate in Archaeological and Cultural Heritage Materials Science) EJD aims to train a new generation of creative and entrepreneurial ESR able to face current and future challenges in Archaeological/Cultural Heritage protection and management and...
Programme: H2020-EU.1.3.1.
Record Number: 211912
Last updated on: 2017-08-31
A new era in personalised medicine: Radiomics as decision support tool for diagnostics and theragnostics in oncology
ID: 766276
Start date: 2017-10-01, End date: 2021-09-30
The high degree of tumour (genomic and phenotypic) heterogeneity influences patient’s response to therapy and hampers wide deployment of personalised medicine for cancer treatment. Thus, there is an imperative need for new technologies that can accurately detect tumour...
Programme: H2020-EU.1.3.1.
Record Number: 211911
Last updated on: 2017-08-31
EXPLORING THE NEUROLOGICAL EXPOSOME
[PROJECT] NEUROSOME - EXPLORING THE NEUROLOGICAL EXPOSOME
ID: 766251
Start date: 2017-10-01, End date: 2021-09-30
The main objective of NEUROSOME is to develop an integrative biology-based framework starting from human biomonitoring data to unravel causal associations among the genetic predisposition, cumulative exposure to multiple environmental chemicals and neurological disorders. The...
Programme: H2020-EU.1.3.1.
Record Number: 211910
Last updated on: 2017-08-31
Super-resolution optical microscopy of nanosized pore dynamics in endothelial cells
ID: 766181
Start date: 2018-01-01, End date: 2021-12-31
DeLIVER will train a new generation of ESRs in the development and application of newly developed high speed and high resolution imaging tools in biomedical research. ESRs will be cross-pollinated with concepts and skills in physics and biomedicine, in particular in...
Programme: H2020-EU.1.3.1.
Record Number: 211909
Last updated on: 2017-09-04
Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational brain tumour research, cancer systems medicine and integrative multi-omics
ID: 766069
Start date: 2017-09-01, End date: 2021-08-31
Glioblastoma (GBM) is the most frequent, aggressive and lethal of all brain tumours. It has a universally fatal prognosis with 85% of patients dying within two years. New treatment options and effective precision medicine therapies are urgently required. This can only be...
Programme: H2020-EU.1.3.1.
Record Number: 211908
Last updated on: 2017-08-31
12 3 4 5 6 7 8 9 10 > >| 
List retrieved on: 2017-11-21
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top